Archive — US — techcrunch
OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3Bvaluation
Chai Discovery, an AI-focused biotech startup backed by OpenAI, raised $130 million in a Series B funding round, achieving a $1.3 billion valuation. The funding will further its development of AI models for drug discovery, aiming to create novel antibodies. The startup has now secured over $225 million in total funding as it advances its innovative approach to biotech.
Key points
- Chai Discovery raised $130 million in Series B funding, led by General Catalyst and Oak HC/FT.
- Total funding for Chai Discovery exceeds $225 million.
- The company focuses on AI to expedite drug development, specifically predicting biochemical interactions.
- Chai introduced its latest model, Chai 2, which improves success rates in de novo antibody design.
- Founded in 2024, co-founder Josh Meier has a background in machine learning and previously worked at OpenAI.
Why it matters
- The raise reflects the growing trend in biotech where AI is used to fast-track drug discovery.
- In 2025, AI-driven innovations in healthcare, particularly drug development, are expected to reshape the industry.
- Chai Discovery's approach aligns with broader industry movements towards computational drug design.
Chai Discovery's successful funding round underscores the increasing role of AI in biotechnology, positioning it as a significant player in the transformative landscape of drug development.